Jefferies Group’s Amicus Therapeutics FOLD Stock Holding History

Jefferies Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-39,100	Closed	-$903K	–	1750
2020 Q4	$903K	Hold	39,100	–	–	0.01%	974
2020 Q3	$552K	Buy	+39,100	New	+$570K	0.01%	959
2020 Q2	–	Sell	-5,600	Closed	-$52K	–	1577
2020 Q1	$52K	Sell	5,600 -205,000	-97%	-$1.95M	﹤0.01%	1871
2019 Q4	$2.05M	Buy	+210,600	New	+$1.93M	0.02%	1044
2019 Q3	–	Sell	-200,000	Closed	-$2.5M	–	2804
2019 Q2	$2.5M	Buy	+200,000	New	+$2.54M	0.02%	801
2016 Q2	–	Sell	-2,000	Closed	-$17K	–	2223
2016 Q1	$17K	Buy	+2,000	New	+$14.2K	﹤0.01%	2103

Other funds holding FOLD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Jefferies Group's FOLD Position: Q4 2021 in Review

Jefferies Group sold out of Amicus Therapeutics (FOLD) in Q4 2021, closing a stake of 25,829 shares — an estimated $247K sold.

Jefferies Group first reported a position in FOLD in Q3 2014 and held it in 13 quarters. The position peaked at $729K in Q2 2019. 223 funds tracked by Wall St. Rank hold FOLD as of Q4 2021.

Jefferies Group reported no remaining Amicus Therapeutics position as of Q4 2021 after selling out during the quarter.
Jefferies Group sold 25,829 Amicus Therapeutics shares in Q4 2021, an estimated $247K.
Jefferies Group first reported a position in Amicus Therapeutics in Q3 2014 and held it in 13 quarters.
Jefferies Group's Amicus Therapeutics position peaked at $729K in Q2 2019.
223 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.